Phase 2/3Completed
Semaglutide in Women With Polycystic Ovary Syndrome and Obesity
Comparison Between the Effects of Low-Dose Semaglutide With Metformin vs. Metformin Alone Over Metabolic Profile in Obese Polycystic Ovary Syndrome: A Phase II Randomized Controlled Trial
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (Academic or other)
- Enrolment
- 31 enrolled
- Conditions
- Polycystic Ovary Syndrome (PCOS) Women; Obesity
- Interventions
- Metformin with Semaglutide
- Ages
- children, adults
- Registry
- NCT06896981
Full record on ClinicalTrials.gov
From the registry
Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder that is frequently associated with metabolic features, including obesity. Improvement of metabolic manifestations helps in the control of symptoms, including subfertility. Metformin has been commonly used to decrease insulin resistance and weight in PCOS patients suffering from obesity. Glucagon-like peptide (GLP-1) agonist semaglutide is also effective in managing different metabolic features, including obesity and insulin resistance. There is limited data about using a combination of semaglutide and metformin in women with PCOS suffering from obesity. This study aims to compare the metabolic changes after giving a combination of low-dose semaglutide and metformin vs. metformin alone over 12 weeks among women with PCOS and obesity. This open label randomized trial will be conducted in the Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University (BSMMU). After obtaining informed written consent, a total of 30 patients with PCOS and obesity will be enrolled conveniently (sampling) in the study as per…
Primary outcomes
- Weight
- Body mass index
- Waist circumference
- Hip circumference
History
Last registry update
Study completion
Primary completion
Registered
Started